Zepbound activates both GIP and GLP-1 receptors, meaning it has a dual mechanism of action, compared to semaglutide and orforglipron, which only activate GLP-1 receptors
WADA bans substances that lack regulatory approval for human use even if they are not specifically performance-enhancing
Rimonabant, the first selective central cannabinoid (CB1) receptor antagonist, was not approved by the FDA because of concerns regarding psychiatric adverse events including depression, anxiety and suicidal ideation [20]
PMID: 6391926
Highly effective medications such as GLP-1 receptor agonists have transformed clinical outcomes, producing substantial and sustained weight reduction while improving metabolic health
I feel rejuvenated, not just physically, but mentally as well. Victor Gonzalez My experience with Regenics has been nothing short of exceptional